Methylated spirit 70%

Indications

• Anesthesia (historically)
• Induction of dissociative anesthesia
• Research purposes in neuropharmacology

Dosage

Children: There are no established pediatric dosages for PCP, and its use in children is not recommended.

Adults: Dosage should be guided by clinical context and individual response, as this substance is not used in standard medical practice due to its potential for abuse and adverse effects.

Mechanism of action

PCP binds to a site within the ion channel of the NMDA receptor, blocking the influx of positive ions such as calcium and sodium. This inhibition prevents neuronal depolarization and disrupts normal neurotransmission, leading to its psychoactive effects. Additionally, PCP's interaction with the GluN2D subunit of the NMDA receptor has implications for its impact on motor function.

Pharmacodynamics

Phencyclidine exhibits its primary effects through NMDA receptor antagonism, leading to decreased excitatory neurotransmission in the brain. This results in a range of behavioral and physiological changes, including dissociation, hallucinations, and altered sensory perceptions. The drug's effects are dose-dependent and can lead to significant motor impairment due to its action on the NMDA receptor pathways.

Pharmacokinetics

PCP is rapidly absorbed and distributed throughout the body. It has a relatively high volume of distribution and is primarily metabolized in the liver. The elimination half-life can vary significantly but is generally in the range of several hours. PCP is excreted mainly in urine, and its metabolites can be detected for a prolonged period after use.

Pregnancy

There are no adequate studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether phencyclidine is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific medication guidelines for dosing.

Adults: Refer to specific medication guidelines for dosing.

Dosage

Children: Refer to specific drug formulation guidelines as methylated compounds encompass a wide range of pharmacological agents, each with its own dosing recommendations.

Adults: Refer to specific drug formulation guidelines as methylated compounds encompass a wide range of pharmacological agents, each with its own dosing recommendations.

Mechanism of action

Methylation can affect the pharmacokinetics of drugs by influencing their solubility, absorption, distribution, metabolism, and excretion. Methylated drugs may have enhanced or reduced activity compared to their unmethylated counterparts, depending on the target receptors and pathways involved. In the context of neurotransmitter metabolism, for example, methylation can lead to the production of active metabolites that exert their effects on the central nervous system.

Pharmacodynamics

The pharmacodynamics of methylated compounds can vary widely depending on the specific drug and its receptor interactions. Methylation can enhance lipophilicity, allowing for better penetration through biological membranes, which may increase the drug's potency or duration of action. Additionally, methylation can affect the binding affinity of a drug to its target, influencing the therapeutic outcome.

Pharmacokinetics

The pharmacokinetics of methylated compounds is influenced by their chemical structure, which affects their absorption, distribution, metabolism, and excretion. Methylated drugs may exhibit altered half-lives due to changes in metabolic pathways. For example, methylation can either activate or deactivate a drug, depending on the metabolic enzymes involved. The presence of methyl groups can also impact the drug's stability and solubility in biological fluids.

Pregnancy

The safety of methylated compounds during pregnancy varies depending on the specific compound and its pharmacological properties. It is essential to assess the benefits and risks before prescribing.

Breast-feeding

Methylated compounds may be excreted in breast milk; caution is advised when administering these medications to breastfeeding mothers.

Storage

Store in a cool, dry place away from light. Specific storage conditions can vary based on the specific methylated compound.

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Indications

• Antiseptic use
• Solvent in pharmaceutical preparations
• Management of alcohol withdrawal syndrome
• Treatment of methanol poisoning (as an antidote)

Dosage

Children: Refer to specific medical guidelines or formularies for dosing information, as it varies widely based on the indication and formulation used.

Adults: Refer to specific medical guidelines or formularies for dosing information, as it varies widely based on the indication and formulation used.

Mechanism of action

Ethanol acts primarily by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, leading to increased inhibitory neurotransmission. It also inhibits the N-methyl-D-aspartate (NMDA) receptor, which contributes to its depressant effects. Additionally, ethanol affects the release of various neurotransmitters, including dopamine, which plays a role in the reward pathway and contributes to its addictive properties.

Pharmacodynamics

Ethanol's pharmacodynamic effects are dose-dependent. Low doses can produce mild euphoria, relaxation, and impaired motor coordination. As the dose increases, effects can progress to sedation, respiratory depression, and potentially coma or death in cases of severe intoxication. Chronic use can lead to tolerance and dependence, with withdrawal symptoms occurring upon cessation.

Pharmacokinetics

Ethanol is rapidly absorbed from the gastrointestinal tract, with peak blood concentrations occurring within 30 to 90 minutes after ingestion. It is distributed throughout body water, with a volume of distribution of approximately 0.5 to 0.7 L/kg. Ethanol is metabolized primarily by the liver through the action of alcohol dehydrogenase and aldehyde dehydrogenase, with a typical elimination rate of 10 to 20 mg/dL per hour. It is excreted in urine, breath, and sweat.

Adverse effects

• Nausea
• Vomiting
• Dizziness
• Headache
• Irritation of mucous membranes
• Depression of the central nervous system

Interactions

• Increased sedation with other CNS depressants
• Potential enhancement of effects of certain medications metabolized by the liver

Precautions

• Use with caution in patients with a history of substance abuse
• Monitor for signs of excessive sedation or respiratory depression
• Avoid use in patients with known hypersensitivity to alcohol or other ingredients

Pregnancy

Alcohol is generally advised against during pregnancy due to risks of fetal alcohol spectrum disorders and other complications.

Breast-feeding

Alcohol can pass into breast milk, and breastfeeding mothers should limit intake to avoid potential effects on the infant.

Storage

Store in a cool, dry place away from light and out of reach of children. Keep tightly closed.

Formulations

• Spirit (ethanol-based liquid)
• Spirit of ammonia
• Spirit of camphor
• Spirit of turpentine

Dosage

Children: Refer to specific product information for details on use as a coloring agent in formulations.

Adults: Refer to specific product information for details on use as a coloring agent in formulations.

Mechanism of action

The mechanism of action for violet dyes generally involves their ability to absorb specific wavelengths of light, which contributes to their coloring properties. In the context of pharmacology, they do not possess therapeutic effects but rather serve a functional role in drug formulation.

Pharmacodynamics

As a coloring agent, violet dyes do not exhibit pharmacodynamic properties associated with therapeutic agents. They do not interact with biological targets in the manner that active pharmaceutical ingredients do, and their primary role is to provide color rather than therapeutic efficacy.

Pharmacokinetics

Violet dyes, being non-active agents, do not undergo typical pharmacokinetic processes such as absorption, distribution, metabolism, and excretion in the same way that active drugs do. Their presence in formulations is primarily for aesthetic purposes, and they are typically excreted unchanged.

Pregnancy

Safety not established; consult healthcare provider.

Breast-feeding

Safety not established; consult healthcare provider.

Storage

Store in a cool, dry place, away from light.

Mechanism of action

The N-methyl-D-Aspartate (NMDA) receptor, a type of ionotropic receptor, is found on the dendrites of neurons and receives signals in the form of neurotransmitters. It is a major excitatory receptor in the brain. Normal physiological function requires that the activated receptor fluxes positive ions through the channel part of the receptor. PCP enters the ion channel from the outside of the neuron and binds, reversibly, to a site in the channel pore, blocking the flux of positive ions into the cell. PCP therefore inhibits depolarization of neurons and interferes with cognitive and other functions of the nervous system. Noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonists evoke a behavioral and neurobiological syndrome in experimental animals. We previously reported that phencyclidine (PCP), an NMDA receptor antagonist, increased locomotor activity in wildtype (WT) mice but not GluN2D subunit knockout mice. Thus, the aim of the present study was to determine whether the GluN2D subunit is involved in PCP-induced motor impairment. PCP or UBP141 (a GluN2D antagonist) induced potent motor impairment in WT mice but not GluN2D KO mice. By contrast, CIQ, a GluN2C/2D potentiator, induced severe motor impairment in GluN2D KO mice but not WT mice, suggesting that the GluN2D subunit plays an essential role in the effects of PCP and UBP141, and an appropriate balance between GluN2C and GluN2D subunits might be needed for appropriate motor performance. The level of the GluN2D subunit in the mature mouse brain is very low and restricted. GluN2D subunits exist in brainstem structures, the globus pallidus, thalamus, and subthalamic nucleus. We found that the expression of the c-fos gene increased the most among PCP-dependent differentially expressed genes between WT and GluN2D KO mice, and the number of Fos-positive cells increased after PCP administration in the basal ganglia motor circuit in WT mice but not GluN2D KO mice. These results suggest that the GluN2D subunit within the motor circuitry is a key subunit for PCP-induced motor impairment, which requires an intricate balance between GluN2C- and GluN2D-mediated excitatory outputs. Prepulse inhibition (PPI) is an example of sensorimotor gating and deficits in PPI have been demonstrated in schizophrenia patients. Phencyclidine (PCP) suppression of PPI in animals has been studied to elucidate the pathological elements of schizophrenia. However, the molecular mechanisms underlying PCP treatment or PPI in the brain are still poorly understood. In this study, quantitative phosphoproteomic analysis was performed on the prefrontal cortex from rats that were subjected to PPI after being systemically injected with PCP or saline. PCP downregulated phosphorylation events were significantly enriched in proteins associated with long-term potentiation (LTP). Importantly, this data set identifies functionally novel phosphorylation sites on known LTP-associated signaling molecules. In addition, mutagenesis of a significantly altered phosphorylation site on xCT (SLC7A11), the light chain of system xc-, the cystine/glutamate antiporter, suggests that PCP also regulates the activity of this protein. Finally, new insights were also derived on PPI signaling independent of PCP treatment. This is the first quantitative phosphorylation proteomic analysis providing new molecular insights into sensorimotor gating. Phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate receptor antagonist, induces psychotomimetic effects in humans and animals. Administration of PCP to rodents is used as a preclinical model for schizophrenia; however, the molecular mechanisms underlying the symptoms remain largely unknown. Acute PCP treatment rapidly induces behavioral and cognitive deficits; therefore, post-translational regulation of protein activity is expected to play a role at early time points. We performed mass-spectrometry-driven quantitative analysis of rat frontal cortex 15, 30, or 240 min after the administ

Pharmacodynamics

Phencyclidine works primarily as an NMDA receptor antagonist, which blocks the activity of the NMDA Receptor.